Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rapidscan Pharma Solutions (RPS) has selected GE Healthcare to promote and distribute selective coronary vasodilator Rapiscan (regadenoson) in the UK and Germany.
Subscribe to our email newsletter
Rapiscan, administered as a non-weight based bolus injection, is used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).
Rapidscan Pharma Solutions said, unlike older agents, Rapiscan requires no dose adjustment for varying body weight and its bolus dosing method is rapid (taking just 10 seconds), cutting out the need for an infusion pump and its set-up.
Rapiscan selectively stimulates the A2A adenosine receptors responsible for the increase in blood flow, but not other adenosine receptors believed to cause undesirable effects that have been associated with the existing pharmacological stress agents.
Rapidscan Pharma Solutions founder, president and CEO Brent Blackburn said Rapiscan was designed to specifically address the needs of patients and healthcare professionals who conduct MPI tests and GE Healthcare is uniquely situated as a leader in the field of cardiac imaging and molecular diagnostics to efficiently introduce Rapiscan to the UK and German healthcare communities.